Alerta

CRISPR-BASED PROGRAMMABLE RNA EDITING

Resumen de: US2025066752A1

CRISPR RNA-guided nucleases are routinely used for sequence-specific manipulation of DNA. While CRISPR-based DNA editing has become routine, analogous methods for editing RNA have yet to be established. Here we repurpose the type III-A CRISPR RNA-guided nuclease for sequence-specific cleavage of the SARS-COV-2 genome. The type III cleavage reaction is performed in vitro using purified viral RNA, resulting in sequence-specific excision of 6, 12, 18 or 24 nucleotides. Ligation of the cleavage products is facilitated by a DNA splint that bridges the excision and RNA ligase is used to link the RNA products before transfection into mammalian cells. The SARS-COV-2 RNA is infectious and standard plaque assays are used to recover viral clones. Collectively, this work demonstrates how type III CRISPR systems can be repurposed for sequence-specific editing of RNA viruses including SARS-COV-2 and more generally for gene therapy.

NEUTRALISING ANTIBODIES AND USES THEREOF

Resumen de: US2025066455A1

The present invention relates to antibodies or antigen-binding fragments thereof that neutralise SARS-CoV-2, and uses thereof.

ANTI-SARS-CoV-2 SPIKE (S) ANTIBODIES AND THEIR USE IN TREATING COVID-19

Resumen de: US2025066456A1

Infectious diseases remain a problem throughout the world. The outbreak of sudden acute respiratory syndrome coronavirus 2 (SARS-Co V-2) has infected more than 640 million people worldwide. SARS-Co V-2 causes the disease COVID-19. Mutations in the SARS-CoV-2 S spike protein enable SARS-CoV-2 variants to escape neutralizing monoclonal antibodies produced from previous infection with SARS-CoV2 or by vaccination. The present invention provides antibodies that bind to the SARS-Co V-2 Spike (S) protein. The invention further relates to pharmaceutical compositions, immunotherapeutic compositions, and methods using the aforementioned antibodies that bind to the SARS-CoV-2 Spike (S) protein.

Composition for Administration of Double-Stranded Oligonucleotide Structures Using Ultrasonic Nebulizer for Prevention or Treatment of Respiratory Viral Infection Including COVID-19, Pulmonary Fibrosis Caused by Viral Infection, or Respiratory Diseases

Resumen de: US2025066787A1

The present invention relates to a composition for administering a double-stranded oligonucleotide structure using an ultrasonic nebulizer. According to the method, the double-stranded oligonucleotide according to the present invention forms self-assembled nanoparticles, which are 90 nm in size and have a neutral charge, and it is possible to deliver the double-stranded oligonucleotide specifically to the nasal cavity and lungs while maintaining not only the same concentration, molecular weight, purity, nanoparticle size, and osmolality as those of the stock material but also the target gene inhibitory activity without cytotoxicity. Thus, the present invention may be useful for the prevention or treatment of respiratory viral infections including COVID-19, pulmonary fibrosis caused by viral infection, or respiratory diseases.

Ribonucleoside Analogues Against -Sars-Cov-2

Resumen de: US2025066365A1

The invention relates to nucleoside derivatives of formula (I), wherein R has the same meaning as that defined in the claims and the description. The present invention also relates to pharmaceutical compositions comprising such compounds and to uses of such compounds and compositions for the treatment or prevention of viral infections, more in particular infections caused by RNA virus, such as coronavirus infections.

Novel chimpanzee adenovirus vector, construction method therefor, and application thereof

Resumen de: US2025066740A1

A chimpanzee adenovirus vector from newly discovered and isolated chimpanzee adenovirus with unique HVR sequences and a method of its construction and application thereof, with higher viral titer, and provides a method for determining its viral titer. The chimpanzee adenovirus circular vector is constructed through a shuttle plasmid, and knocks out E1 and E3 to construct a replication-defective chimpanzee adenovirus vector. The chimpanzee adenovirus vector described in this article has no preexisting antibody in the population, and the knockout of E1 and E3 is safe. At the same time, it is significantly different from human adenovirus type 5 E1 in 293 cells, which can greatly avoid recovery mutation (RCA) and make it safer. The novel coronavirus vaccine has strong stability and does not cause mutations after multiple passages, and it can induce strong humoral immunity and cellular response in mouse models.

ANTIVIRALS TARGETING PHOSPHATIDIC ACID PHOSPHATASE (PAP)

Resumen de: US2025064758A1

Host-targeting antiviral agents against conserved phosphatidic acid phosphatase (PAP) pathways that act as broad-spectrum treatment strategies for different coronaviruses, such as variants of SARS-COV-2, have been developed. Compositions of anti-coronavirus agent(s) that acts via the host PAP pathway and methods of use thereof for treating and preventing diseases and disorders associated with coronaviruses are provided. An exemplary anti-coronavirus agent that acts via the PAP pathway is propranolol. Compositions of propranolol and methods of use thereof for treating and preventing diseases and disorders associated with coronaviruses are provided. In some forms, the compositions and methods treat or prevent one or more symptoms associated with infection by SARS-COV-2 wild type, Delta variants, Omicron variants and MERS-COV in a subject in need thereof.

N4-HYDROXYCYTIDINE AND DERIVATIVES AND ANTI-VIRAL USES RELATED THERETO

Resumen de: US2025064844A1

This disclosure relates to certain N4-hydroxycytidine derivatives, pharmaceutical compositions, and methods related thereto. In certain embodiments, the disclosure relates to the treatment or prophylaxis of human coronavirus 2019-nCoV.

KETOAMIDE DERIVATIVES AND PHARMACEUTICAL USES THEREOF

Resumen de: US2025064789A1

A class of ketoamide derivatives and pharmaceutical uses thereof are provided. Specifically provided are the compound represented by formula I, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or an optical isomer thereof, or a deuterated compound thereof. The compound can effectively inhibit the activity of SARS-CoV-2 Mpro, and can be used in the manufacturer of SARS-CoV-2 Mpro inhibitors, blocking the replication and transcription of SARS-CoV-2 virus in patients. The compound can be used in preparing SARS-CoV-2 Mpro inhibitors, anti-SARS-CoV-2 medicaments, as well as the medicaments for preventing and/or treating Corona Virus Disease 2019 (COVID-19).

ANTI-HUMAN CORONAVIRUS COMPOSITION

Resumen de: EP4512255A1

An objective of the present invention is to provide a nonpharmaceutical anti-human coronavirus composition that prevents human coronavirus infections, the onset of the infections, or aggravation of symptoms of the infections. The anti-human coronavirus composition according to the present invention includes an exopolysaccharide produced by a lactic acid bacterium in genus Lactobacillus as an active component. The lactic acid bacterium in the genus Lactobacillus may belong to a Lactobacillus delbrueckii species. The lactic acid bacterium in the genus Lactobacillus may specifically be Lactobacillus delbrueckii subsp. bulgaricus OLL1073R-1 (FERM BP-10741).

SARS-COV2 MAIN PROTEASE INHIBITORS

Resumen de: AU2023320566A1

The present disclosure relates to compounds of Formula I: and pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, useful in the treatment of treating viral infections, for example, coronaviridae infections.

ANTISENSE OLIGONUCLEOTIDES (ASOS) THAT SUPPRESS SARS-COV-2 REPLICATION

Resumen de: US2025059544A1

Provided herein are antisense oligonucleotides for use in targeting SARS-CoV-2. Also provided herein are compositions comprising such oligonucleotides and methods for administering the oligonucleotides or compositions thereof to a subject for the purpose of treating or preventing a SARS-CoV-2 infection.

PSEUDOVIRUS BASED NEUTRALIZATION ASSAY FOR EVALUATING VACCINE IMMUNOGENICITY

Resumen de: AU2023315949A1

Provided herein are pseudoviruses expressing a SARS-CoV-2 S glycoprotein. Also provided herein are assays that employ the pseudoviruses to evaluate the immunogenicity of a biological sample against a SARS-CoV-2 virus or variant thereof. Also provided herein are methods of evaluating the immunogenicity of a COVID-19 vaccine using the assays.

CORONAVIRUS VACCINE

Resumen de: AU2025200483A1

Abstract This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. These methods and agents are, in particular, useful for the prevention or treatment of coronavirus infection. Administration of RNA disclosed herein to a subject can protect the subject against coronavirus infection. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen. Administering to the subject RNA encoding vaccine antigen may provide (following expression of the RNA by appropriate target cells) vaccine antigen for inducing an immune response against vaccine antigen (and disease-associated antigen) in the subject. In December 2019, a pneumonia outbreak of unknown cause occurred in Wuhan, China and it became clear that a novel coronavirus (severe acute respiratory syndrome coronavirus 2; SARS-CoV-2) was the underlying cause. The genetic sequence of SARS-CoV-2 became available to the WHO and public (MN908947.3) and the virus was categorized into th

METHOD OF DETECTION OF SEVERE ACUTE RESPIRATORY SYNDROME (SARS)-COVID (SARS-CoV)

Resumen de: US2025062038A1

A method of detecting SARS-COV in a sample includes contacting a metal-organic framework with at least one fluorophore-labeled single-stranded probe deoxyribose nucleic acid (DNA) to form a biosensor. The metal-organic framework of the method is zeolitic imidazolate framework-8 (ZIF-8), and the fluorophore-labeled single-stranded probe DNA (p-DNA) has a fluorescence signal at 513 to 517 nm. The method further includes contacting the sample with the biosensor in a solution, and the sample comprises a target sequence of SARS-COV. The target sequence of SARS-COV and the fluorophore-labeled single-stranded p-DNA of the method hybridize to form a double-stranded product. Following the step of the hybridization forming the double-stranded product, the method includes detecting the double-stranded product by observing a change in fluorescence.

METHOD AND REAGENT FOR TESTING NOVEL CORONAVIRUS

Resumen de: US2025059613A1

A method for testing a novel coronavirus, the method including steps of: mixing a specimen sample collected from a subject, or a mixed liquid of the specimen sample and a medium, with a specimen treatment liquid containing sodium hydroxide as a main component, to obtain a mixed liquid; incubating the mixed liquid; adding a master mix containing a reaction liquid, an internal standard substance, a primer, a probe, a reverse transcriptase, and a PCR enzyme to the mixed liquid after the incubation, to obtain a final mixed liquid; subjecting the final mixed liquid to a reverse transcription reaction treatment; and detecting, through use of the probe, DNA amplified by PCR using the DNA generated by the reverse transcription reaction treatment as a template.

USE OF THERAPEUTIC PEPTIDES

Resumen de: US2025059233A1

Peptides and pharmaceutically acceptable salts thereof and peptide conjugates and pharmaceutically acceptable salts thereof having 5 to 15 amino acids and having an amino acid sequence comprising at least 5 consecutive amino acids from the amino acid sequence LSSTQAQQSX1 (SEQ ID NO:1) for use in treating a subject suffering from or at risk of an inflammatory disease or disorder, schizophrenia or psychosis, a neurodegenerative disease such as Parkinson's disease. Alzheimer's disease, or ALS, a gastrointestinal disease or disorder such as irritable bowel syndrome, inflammatory bowel disease. Crohn's disease, or constipation, pain (e.g., visceral pain), rheumatoid arthritis, migraine, headache, substance abuse (e.g., substance use disorder such as drug use disorder, polysubstance use disorder, alcohol use disorder, or nicotine use disorder, tobacco use disorder), drug addiction, a seizure disorder, major depressive disorder, atypical depression, a major depressive episode (MDE) (e.g., atypical MDE), treatment resistant depression, depression in the presence of a neurodegenerative disease, cognitive impairment, COVID-19 related cognitive impairment and/or depression, ADHD, an autism spectrum disorder, a pervasive developmental disorder, atypical autism, multiple sclerosis, PTSD, a sleep disorder such as insomnia, daytime fatigue, or REM sleep behavior disorder, or for use in improving sleep in a subject.

PLPRO INHIBITORS

Resumen de: US2025059159A1

Provided herein are novel compounds (e.g., Formula X or Y), pharmaceutical compositions, and methods of using the same. The compounds herein can typically inhibit PLpro activities. The compounds herein can also be used for treating a variety of diseases or disorders, such as viral infection caused by a coronavirus such as SARS-CoV-2.

LIGANDS AND METHODS OF MAKING LIGANDS FOR AFFINITY CAPTURE ON A SURFACE OF MRNA IN A SOLUTION

Resumen de: US2025059528A1

Separation constructs such as membranes, porous beads, etc. are modified with a plurality of oligomeric ligands. The ligands are bound to the surface of the separation substrates via linker constructs such as acrylate groups or azide groups, e.g., via Single-Electron Transfer-Living Radical Polymerization (SET-LRP). A plurality of spacer constructs, such as polyethyleneglycol (PEG) groups and hydrocarbyl groups, separate the linker constructs from oligomer constructs. The oligomer constructs can include between 5% and about 10% guanine and about 90% to about 95% thymine, and can further include between about 20 and about 60 nucleotides including at least 15 thymines and at least 1 guanine. The oligomer constructs exhibit improved binding of mRNA with oligo-dAn tails, e.g., for purification of mRNA production and commercialization, enabling fast, efficient, and continuous production of mRNA vaccines such as those against coronaviruses, e.g., SARS-CoV-2.

DYSREGULATION OF TRAUMA REGULATION PATHWAY TREATMENT AND MONITORING TECHNIQUES

Resumen de: US2025057941A1

The subject matter of the present disclosure generally relates to techniques for addressing or correcting dysregulation of the trauma regulation pathway. The dysregulation may be associated with a physiological condition, such as a SARS-CoV-2 viral infection. In an embodiment, the techniques include treating dysregulation based on a renin-angiotensin pathway molecule or cell and/or a splenic pathway molecule or cell using targeted neuromodulation. In an embodiment, neuromodulation is used to regulate the immune system, e.g., as an energy-based adjuvant for a vaccine.

APPLICATION OF 10'(Z), 13'(E), 15'(E)-HEPTADECATRIENYL HYDROQUINONE (HQ17(3)) IN TREATING CORONAVIRUS INFECTION

Resumen de: US2025057785A1

The present disclosure relates to use of 10′(Z), 13′(E), 15′(E)-Heptadecatrienyl hydroquinone compound (hereafter “HQ17(3)”) represented by the following Formula (12), a pharmaceutically acceptable salt, and/or a solvate and/or a hydrate thereof, and a pharmaceutical composition comprising the above compound, in treating coronavirus infection and diseases caused by the infection, especially SARS-COV-2 infection.

PRODUCTS OF MANUFACTURE AND METHODS FOR TREATING, AMELIORATING OR PREVENTING CORONAVIRUS INFECTION

Resumen de: US2025057803A1

In alternative embodiments, provided are pharmaceutical compositions comprising combinations of drugs, including products of manufacture and kits, and methods for using them, for treating, preventing, ameliorating, slowing the progress of, decreasing the severity of or preventing a coronavirus infection, or a COVID-19 infection, or an infection caused by a virus in the subfamily Orthocoronavirinae, or a virus in the family Coronaviridae, or a virus in the order Nidovirales. In alternative embodiments, combinations, or cocktails, of a drug or drugs as provided herein are administered either enterally, parenterally and/or by inhalation. In alternative embodiments, combinations, or cocktails, of drugs as provided herein are used to block intracellular metabolic pathways and prevent progression of the infection to clinical illness and death. In alternative embodiments, novel aerosol, spray or mist or powder formulations for inhalation are provided. In alternative embodiments, provided are therapeutic combinations of drugs or a drug, a pharmaceutical dosage form, a drug delivery device, or a product of manufacture, comprising: opaganib or YELIVA™, or opaganib or YELIVA™ and oral and/or inhaled chloroquine (or ARALEN™), chloroquine phosphate, chloroquine diphosphate and/or hydroxychloroquine (optionally, PLAQUENIL™), with or without azithromycin, wherein optionally each or all of the opaganib, the chloroquine (or ARALEN™), chloroquine phosphate, chloroquine diphosphate an

IMMUNE MEMORY ENHANCED PREPARATIONS AND USES THEREOF

Resumen de: US2025057940A1

Formulations and preparations having immune memory enhanced properties are disclosed that provide for enhancing immune response against a tumor growth, cancer, infectious agent, bacteria, virus or other infectious or non-infectious agent. The vaccine formulation includes an immune memory invoking component, such as an antigen of an infectious agent, virus (e.g., Rabies), bacteria, prion, neo-antigen or other moiety antigen, and a targeted antigen (e.g., a harvested tumor tissue (B-cell, T-cell, epitopes)). The vaccine formulation/preparations may comprise a target infectious agent protein/peptide component (such as a SARS-Cov-2 spike protein epitope) mixed with, or fused to (or otherwise conjugated) an immune-memory associated viral antigen (such as Rabies, polio, or other peptide/protein antigen or peptide or fragment thereof).

ALPHA-1 ANTITRYPSIN PRODUCED FROM YEAST FOR USE IN THE TREATMENT OF VIRAL INFECTIONS

Resumen de: US2025057927A1

A recombinant alphal-antitrysin (AAT) protein or a fragment thereof expressed in a genetically modified yeast for use in the treatment of a viral infection and/or lung inflammation. In one embodiment, the viral infection is a viral respiratory infection, preferably a coronavirus infection, such as a SARS CoV infection, more preferably SARS-CoV-2. Also disclosed is a method of producing recombinant AAT protein or fragment(s) thereof from genetically modified yeast. In embodiments, the method includes the steps of culturing a genetically modified yeast comprising an exogenous nucleic acid molecule with an AAT-encoding region operably linked to a promoter or promoter/enhancer combination, expressing recombinant AAT in the cultured yeast, and isolating recombinant AAT from the culture. In embodiments, the recombinant AAT produced from yeast is prepared in a pharmaceutical composition, such as a solution, preferably suitable for nebulization and subsequent inhalation by a subject.

FREEZE-DRIED VIRAL COMBINATION VACCINE COMPOSITIONS AND PROCESS FOR PREPARATION THEREOF

Nº publicación: US2025057939A1 20/02/2025

Solicitante:

SERUM INSTITUTE OF INDIA PRIVATE LTD [IN]
CODAGENIX INC [US]
Serum Institute Of India Private Limited,
Codagenix Inc